We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: nigel bates11/20/2018 5:43:44 AM
   of 3158
Reuters) - U.S. medical device maker Boston Scientific Corp (BSX.N) said it had agreed a 3.3 billion pound cash deal to buy Britain's BTG Plc (BTG.L) to bolster its capabilities in interventional medicine.

The offer of 840 pence per share represents a premium of 36.6 percent to BTG's close of 615 pence on Monday.

Shares of BTG soared more than 35 percent to 832 pence, their highest level since Jan. 2015, on Tuesday. Up to Monday's close, the stock had slipped 19.3 percent this year.

Boston Scientific said BTG's interventional portfolio - using devices to deliver drugs to affected organs - would augment its capabilities in important areas of unmet need such as cancer and pulmonary embolism.

BTG, which has long produced drugs to treat overdoses and rattlesnake bites, has focussed on interventional medicine in recent years, for example producing beads that target tumours.

Boston Scientific's chairman and CEO Michael F. Mahoney said the addition of these therapies to our portfolio would ultimately advance patient care in ways that could not be realised by either company alone, while also providing a strong return for investors.

BTG said it considered the terms of the offer to be fair and reasonable and it planned to recommend the deal to shareholders.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext